Key Takeaways Revvity will report Q4 results on Feb. 2, with revenue expected to rise 5.2% year over year.RVTY's Life Sciences unit shows early demand recovery, driven by software growth and better instrument trends.RVTY's Diagnostics demand outside China is solid, but China reimbursement pressure remains a concern.Revvity, Inc. (RVTY) is slated to report fourth-quarter 2025 results on Feb. 2, before market open.In the last reported quarter, the company delivered an earnings surprise of 3.51%. RVTY’s earnin ...

At Revvity, "impossible†is inspiration, and "can't be done†is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. WALTHAM, Mass.--(BUSINESS WIRE) ...

Core Insights - The presentation is led by Revvity's CEO, Prahlad Singh, who highlights the company's progress over the past year [1] - Revvity has undergone a portfolio transformation, evolving from an industrial company with a focus on analytical services, small molecule preclinical life sciences, and diagnostics [3] Financial Overview - The financial figures and growth rates discussed are based on guidance from the 3Q earnings call dated October 27, 2025 [2]

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - Revvity is a $2.8 billion company, with revenue split roughly equally between life sciences and diagnostics segments [4] - The company has undergone a portfolio transformation, moving from a legacy industrial company to a focus on high-growth life sciences and diagnostics [2][3] Key Financial Metrics - Approximately 85% of revenue is recurring, derived from consumables, assets, services, and software [4] - Life sciences solutions have a five-year average organic growth rate of high single digits and operating margins above 30% [5] - Diagnostics revenue is about $1.4 billion, with a similar growth rate and operating margins around 25% [6] Strategic Initiatives - Revvity aims to be a key player in the drug development lifecycle, providing comprehensive solutions from early discovery to commercialization [9] - The company has launched AI initiatives, including Transcribe AI, which improves workflow speed by 40% for clinical lab customers [10][11] - A partnership with Eli Lilly aims to accelerate AI-enabled drug discovery through the Signals Synthetica platform [11][12] Market Dynamics - The life sciences segment is primarily focused on pharma and biotech, with 75% of customers in these sectors [5] - The diagnostics segment focuses on immunodiagnostics (60% of revenue) and reproductive health (40%) [6] - The company has seen a significant increase in immunodiagnostics revenue from the Americas, which has doubled from 10% to 20% [14] Growth Outlook - For 2026, Revvity expects 2%-3% organic growth, with high single-digit adjusted EPS growth [19][20] - The company anticipates double-digit growth in immunodiagnostics and Signals Software, with mid-single-digit growth in life sciences solutions and reproductive health [20] - The operational excellence initiatives aim for a 28% adjusted operating margin by 2026, with a focus on cost reductions and efficiency improvements [19] Partnerships and Collaborations - Revvity has formed strategic partnerships with Genomics England and Sanofi, focusing on large-scale genomic screening and pediatric disease screening [15][16][46] - The company is exploring opportunities for partnerships in AI and genomics, although specific details are not yet public [54] Challenges and Risks - The company faces headwinds in the Chinese market, particularly in immunodiagnostics, but expects growth to return in the second half of 2026 [50] - The overall market conditions and funding trends in biotech are seen as positive indicators for Revvity's growth [33][58] Conclusion - Revvity is positioned as an innovative life sciences and diagnostics company with a transformed portfolio and a focus on operational excellence, aiming for significant growth and margin expansion in the coming years [21][22]

J.P. Morgan 44th Healthcare Conference Prahlad Singh Chief Executive Officer January 13, 2026 Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to the Company's customers and end-markets, plans concerning business development oppo ...

Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give. ...

| RVTY Revvity | | | | --- | --- | --- | | 103 890 J -0.540 -0.52% | | 收盘价 01/12 15:59 美东 | | 110.010 + 6.120 +5.89% | | 盘前价 01/13 04:12 美东 | | 三 7 24 华 5 9 月 ♥ 白选 | | ● 快捷交易 | | 最高价 107,000 | 开盘价 106.450 | 成交量 88.46万 | | 最低价 102.710 | 昨收价 104.430 | 成交额 9207.07万 | | 平均价 104.084 | 市福率 M 52.21 | 总市值 117.79亿 (--) | | 振 幅 4.11% | 市盈率(静) 47.22 | 总股本 1.13亿 | | 换手率 0.85% | 市净率 1.596 | 流通值 108.06亿 | | 52周最高 128.000 委 比 25.93% | | 流通股 1.04亿 | | 52周最低 81.299 | 量 比 0.73 | 每 手 1股 | | 历史最高 201.224 | 股息TTM 0.280 | | | 历史 ...

Group 1: Market Movements - Several biotech and healthcare companies experienced notable gains in after-hours trading, driven by earnings updates, guidance announcements, and broader investor sentiment [1] - FibroBiologics, Inc. (FBLG) led with a 7.68% increase, closing at $0.41, suggesting speculative interest or technical momentum [1] - Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary results for Q4 and full year 2025, along with revenue guidance for Q1 2026 [2] - Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49, continuing a trend of volatility despite no new news [2] - Revvity, Inc. (RVTY) gained 4.92% to close at $109.00, with investors likely reacting to a previous collaboration announcement with Eli Lilly [3] - Option Care Health, Inc. (OPCH) rose 3.28% to $33.11 after releasing preliminary unaudited financial results for Q4 and full year 2025, along with guidance for 2026 [4] - Actinium Pharmaceuticals, Inc. (ATNM) added 3.02% to close at $1.34, reflecting investor activity in the broader biotech sector [4] - Design Therapeutics, Inc. (DSGN) gained 1.97% to $9.30, indicating continued interest despite no specific news [5] Group 2: Company-Specific Developments - FibroBiologics, Inc. (FBLG) showed a significant rise without any company-specific news, indicating potential speculative interest [1] - Nyxoah SA (NYXH) provided revenue guidance for Q1 2026, which bolstered investor confidence in its growth trajectory [2] - Revvity, Inc. (RVTY) is expanding access to predictive models through a collaboration with Eli Lilly, aimed at accelerating AI-enabled drug discovery [3] - Option Care Health, Inc. (OPCH) released preliminary financial results and guidance, contributing to its positive after-hours reaction [4]

Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services. ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Inves. ...